泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03880 泰德医药

交易中 09-24 15:09:12

23.060

+0.460

+2.04%

最高23.800	最低22.420	成交量7.00万
今开22.900	昨收22.600	日振幅6.11%
总市值32.70亿	流通市值32.70亿	总股本1.42亿
成交额161.86万	换手率0.05%	流通股本1.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03880","market":"HK","secType":"STK","nameCN":"泰德医药","latestPrice":23.06,"timestamp":1790233200054,"preClose":22.6,"halted":0,"volume":70000,"delay":0,"changeRate":0.020353982300884834,"floatShares":141800000,"shares":141800000,"eps":1.904185294994274,"marketStatus":"交易中","change":0.46,"latestTime":"09-24 15:09:12","open":22.9,"high":23.8,"low":22.42,"amount":1618574,"amplitude":0.061062,"askPrice":23.2,"askSize":500,"bidPrice":23.04,"bidSize":200,"shortable":0,"etf":0,"ttmEps":1.3912480096318256,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790237400000},"marketStatusCode":2,"adr":0,"listingDate":1751212800000,"exchange":"SEHK","adjPreClose":22.6,"openAndCloseTimeList":[[1790213400000,1790222400000],[1790226000000,1790236800000]],"volumeRatio":0.817965,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03880","defaultTab":"news","newsList":[{"id":"1179864906","title":"泰德医药8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1179864906","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179864906?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:51","pubTimestamp":1788425517,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司（股票代码：03880）于2026年9月3日披露2026年8月股份变动月报。公告显示，截至8月31日，公司已发行普通股（H股）总数为141,800,000股，注册资本为人民币141,800,000元。报告期内未有新增发行、回购、注销或库藏股活动，股本结构维持不变。\n公司表示，公告由公司秘书陈祯签署，并确认已遵守香港联交所《上市规则》及相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127273008","title":"泰德医药（03880）拟系统优化治理结构　多项章程及制度修订待临时股东大会表决","url":"https://stock-news.laohu8.com/highlight/detail?id=1127273008","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127273008?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:52","pubTimestamp":1787820759,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司8月27日公告称，董事会已审议通过多项治理文件修订议案，涵盖公司章程、股东会议事规则、董事会议事规则，以及独立非执行董事工作制度和对外担保管理制度。相关修订尚需提交即将召开的临时股东大会表决，其中修订公司章程、股东会议事规则和董事会议事规则须以特别决议案形式获股东批准，其余制度修订以普通决议案表决。临时股东大会具体日期及议程将通过通函形式另行通知全体股东。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774456","title":"泰德医药(03880)建议采纳受限制股份单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774456","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662774456?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:45","pubTimestamp":1787820310,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 发布公告，于2026年8月27日，董事会通过决议，内容有关建议采纳受限制股份单位计划;及建议采纳服务提供者分项限额。鉴于合资格参与者的范围扩大至包括服务提供者，董事会认为，根据上市规则第17.03A条的规定，在计划授权限额内采纳服务提供者分项限额属适当。因此，根据受限制股份单位计划不时授予服务提供者的奖励总数，不得超过截至采纳日期已发行股份总数的1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142629147","title":"泰德医药2026年上半年营收2.35亿元，经调整净利润0.56亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142629147","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142629147?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:38","pubTimestamp":1787819918,"startTime":"0","endTime":"0","summary":"泰德医药公布截至2026年6月30日止上半年财报，报告期内实现营收2.35亿元，同比下降7.6%。期内毛利率为58.0%，同比下降3.1个百分点。经调整净利润为0.56亿元，同比下降46.4%。成本方面，报告期内销售成本约0.99亿元，同比下降0.3%。CRO业务收入达到0.65亿元，同比增长17.8%。CDMO业务则录得1.69亿元，同比下降14.7%。其中，按不同服务模式划分，FFS业务收入约2.10亿元，同比下降10.0%；FTE业务收入0.25亿元，同比增长18.9%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"泰德医药2026年上半年营收2.35亿元，经调整净利润0.56亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100593776","title":"泰德医药（03880）拟推出受限制股份单位计划 规模上限占股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100593776","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100593776?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:38","pubTimestamp":1787819884,"startTime":"0","endTime":"0","summary":"2026年8月27日，泰德医药公告称，公司董事会当日通过决议，拟于临时股东大会上提请股东审议并批准两项议案：一是《2026年泰德医药受限制股份单位计划》；二是“服务提供者分项限额”的设立。因RSU计划发行的新H股须获香港联交所上市及买卖批准。公司表示，如未来需调整服务提供者分项限额，将另行提交股东大会审议。公告最后提醒，RSU计划及服务提供者分项限额的特别决议案均需在即将召开的临时股东大会上表决通过后方可实施。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662977484","title":"泰德医药(03880)公布中期业绩 净利润约5367.7万元 同比减少47.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662977484?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:35","pubTimestamp":1787819722,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 公布2026年中期业绩，收益约2.35亿元，同比减少7.6%;毛利约1.36亿元，同比减少12.3%;净利润约5367.7万元，同比减少47.4%。上半年，该集团继续积极扩充其钱塘及罗克林园区的多肽产能。同时，罗克林园区的翻新及设备安装工程正按计划推进。截至2026年6月30日止六个月，资本开支增加至9890万元，反映集团持续的产能扩充举措。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660348657","title":"泰德医药(03880.HK)拟8月27日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2660348657","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660348657?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:17","pubTimestamp":1786958230,"startTime":"0","endTime":"0","summary":"格隆汇8月17日丨泰德医药(03880.HK)公告，董事会会议将于2026年8月27日(星期四)召开，藉以(其中包括)审议及批准公司及其附属公司截至2026年6月30日止6个月的中期业绩及其刊发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162717331","title":"泰德医药(03880)拟于2026年8月27日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1162717331","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162717331?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:36","pubTimestamp":1786955818,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司（03880）8月17日公告称，公司董事会计划于2026年8月27日（星期四）召开会议，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜。  \n  \n公告显示，董事会现由执行董事徐琪博士（兼董事长兼首席执行官）、李湘博士、李湘莉女士、Cheng Tao女士及李玲梅女士；非执行董事吴一晖先生；以及独立非执行董事于常海博士、朱迅博士、夏心晟先生组成。  \n  \n公司未在公告中披露任何财务数据。待董事会审议通过后，相关中期业绩将另行发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657698357","title":"港股CXO近日股价集体走高，盈警之后的泰德医药(03880)将逆市下跌还是超跌反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657698357?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:22","pubTimestamp":1786069332,"startTime":"0","endTime":"0","summary":"7月31日盘后，泰德医药发布了其26H1财年盈警公告。目前泰德医药尚未迎来连续数个交易日的低点逐步抬高以彻底终结下跌趋势，关键的量能均线也尚未出现明显转折。近日，港股医药概念股集体走高，CXO、创新药板块多点爆发，带动恒生医疗保健指数强势反弹。以8月4日行情为例，港股CXO板块出现一波个股集体走高，其中药明康德股价大涨11.17%，康龙化成和泰格医药均涨超5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NIFE","CXO","VXUS","WX","KCAI","03880","BK4588","BK1141","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169061968","title":"泰德医药7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1169061968","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169061968?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:51","pubTimestamp":1785919909,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司于2026年8月5日发布2026年7月股份变动月报表，报告期为截至2026年7月31日。公告显示，公司普通股H股的已发行股本数量和注册股本在报告期内均维持不变。报告期内，公司无新增发行、购回、注销或库藏股活动，已发行股份及库存股份数目稳定在141,800,000股和0股，符合香港联合交易所有限公司关于最低公众持股量的相关规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655562893","title":"泰德医药(03880)成功完成HEPCLUDEX®原料药之美国FDA上市许可前检查(PLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655562893","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655562893?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:39","pubTimestamp":1785487145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 发布公告，公司全资附属公司中肽生化有限公司位于中国杭州的现行生产质量管理规范生产设施，已成功通过由美国食品及药物管理局开展的上市许可前检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LABU","BK1141","BK4585","03880","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356079","title":"泰德医药(03880)发盈警 预计上半年利润同比减少约44%至51.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356079","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655356079?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:38","pubTimestamp":1785487130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 发布公告，相较于截至2025年6月30日止六个月的数据，董事会预期截至2026年6月30日止六个月：1.收入将介于约人民币2.298亿元至2.392亿元，同比减少约5.7%至9.4%;2.利润将介于约人民币4940万元至5710万元，同比减少约44.0%至51.6%;3.经调整净利润将介于约人民币5140万元至5930万元，同比减少约43.1%至50.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"泰德医药(03880)发盈警 预计上半年利润同比减少约44%至51.6%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148155391","title":"泰德医药（03880）发布高管调整：丁丽君出任首席财务官并兼任董事会秘书 同时更新港办地址","url":"https://stock-news.laohu8.com/highlight/detail?id=1148155391","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148155391?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:36","pubTimestamp":1785487011,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司7月31日公告，公司董事会已通过多项人事及行政调整，自2026年7月31日起生效。公司委任丁丽君女士为首席财务官，负责集团整体财务战略与管理。丁丽君现年50岁，拥有27年财务、业务规划及财务运营管理经验。公司董事会对辞任的吴东澄先生、李玲梅女士表示感谢，并欢迎新任管理层成员履新。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356495","title":"泰德医药(03880)：丁丽君获委任为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356495","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655356495?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:36","pubTimestamp":1785487001,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 发布公告，丁丽君女士已获委任为首席财务官，自2026年7月 31日起生效。丁女士将主要负责本集团的整体财务战略与管理。李女士将继续担任本公司执行董事。自2026年7月31日起，继李女士辞任董事会秘书后，丁女士已获委任为董事会秘书。吴先生及李女士辞任联席公司秘书后，陈桢先生已获委任为本公司公司秘书、授权代表及法律程序代理人，自2026 年7月31日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"泰德医药(03880)：丁丽君获委任为首席财务官","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168086634","title":"泰德医药（03880）发布盈利警告：预计2026年中期利润最多下滑逾五成","url":"https://stock-news.laohu8.com/highlight/detail?id=1168086634","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168086634?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:36","pubTimestamp":1785486978,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司7月31日发布公告称，根据对截至2026年6月30日止六个月未经审计管理账目的初步审阅，预计主要财务指标将出现下滑。公司预计，2026年中期收入将在约2.298亿元至2.392亿元之间，较2025年中期的约2.538亿元下降约5.7%至9.4%。泰德医药提醒投资者，以上数据基于初步评估，未经审计，实际业绩可能与本公告披露的预期存在差异，公司计划于2026年8月底披露中期业绩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164817050","title":"泰德医药（03880）全资子公司通过美国FDA上市许可前检查","url":"https://stock-news.laohu8.com/highlight/detail?id=1164817050","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164817050?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:36","pubTimestamp":1785486961,"startTime":"0","endTime":"0","summary":"2026年7月31日，泰德医药发布自愿公告称，其全资子公司中肽生化有限公司位于杭州的cGMP生产设施已通过美国食品及药物管理局对8.5毫克注射用Hepcludex原料药的上市许可前检查。此前，Hepcludex已于2026年5月22日获得FDA加速批准，成为美国首个也是唯一获批用于治疗慢性丁型肝炎病毒感染的药物。在Hepcludex获批之前，美国尚无FDA批准的HDV治疗方案。\\n\\n泰德医药于2025年在香港联交所主板上市，定位为全球CRDMO企业，业务覆盖美国与中国两地。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146063807","title":"泰德医药更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1146063807","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146063807?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:09","pubTimestamp":1783328943,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司于2026年7月6日披露2026年6月股份变动月报表。公告显示，截至2026年6月30日，公司总股本保持为141,800,000股，与上月持平。公司已发行H股全部在香港联合交易所上市，未设任何库存股份。此外，公告确认公司目前持有足够的公众持股量，符合香港联合交易所《上市规则》以及相关法律法规有关最低公众持股量的要求。公司表示将继续严格遵守香港联合交易所的上市规则和相关法律法规，加强公司治理和信息披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105285217","title":"泰德医药5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1105285217","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105285217?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:51","pubTimestamp":1780476697,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司于2026年6月3日发布的2026年5月证券变动月报表显示，截至2026年5月31日，公司未发生新增发行、回购或库存股变动，股本结构保持稳定。截至2026年5月底，公司已满足在香港联交所上市所要求的公众持股量要求。月报同时显示，公司当月无涉及股份期权、权证或其他可转换证券的相关变动，亦未发生其他协议或安排下的股份变动事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136706347","title":"泰德医药获授权回购不超过已发行股份10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136706347","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136706347?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:46","pubTimestamp":1779893201,"startTime":"0","endTime":"0","summary":"泰德医药日前在公告中披露，董事会已获股东大会特别授权，可于特定期间内于香港联交所回购不超过公司已发行H股总数10%的股份。公司目前已发行H股共1.418亿股，按照公告所载比例测算，回购数量最高可达1418万股。泰德医药已于公告列举自2025年6月至2026年5月期间的H股最高及最低股价，期间波动区间大约介于21.04港元至41.72港元之间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰德医药获授权回购不超过已发行股份10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111257244","title":"泰德医药4月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1111257244","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111257244?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:53","pubTimestamp":1778057615,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司于2026年5月6日发布2026年4月股份变动月报表，披露公司截至2026年4月30日的股本情况。根据公告，公司普通股H股于香港联交所上市，期末已发行H股数量为141,800,000股，每股面值人民币1元，对应已发行股本人民币1.42亿元，与上月末持平。公告显示，报告期内公司未发生新增发行、回购、注销或库藏股变动，现有股本规模保持不变。此外，公司表示已遵守香港联交所《上市规则》及相关法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.medtideinc.com","stockEarnings":[{"period":"1week","weight":0.1783},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0165},{"period":"6month","weight":0.0071},{"period":"1year","weight":-0.2614},{"period":"ytd","weight":-0.2585}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0761},{"period":"6month","weight":-0.0047},{"period":"1year","weight":-0.0507},{"period":"ytd","weight":-0.0311}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"泰德医药（浙江）股份有限公司是一家主要从事多肽的合约研究、开发和生产的中国公司。该公司主要提供合约研究机构（CRO）服务，即多肽新化学实体（NCE）发现合成、合约开发及生产机构（CDMO）服务即多肽化学、制造及控制（CMC）开发以及商业化生产。该公司的服务主要专注于向客户提供活性药物成分（APIs），而非药品。该公司也为客户提供多肽类药物开发、生产、CMC申报支持服务。该公司主要在国内市场和海外市场开展业务。","exchange":"SEHK","name":"泰德医药","nameEN":"MEDTIDE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰德医药(03880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰德医药,03880,泰德医药股票,泰德医药股票老虎,泰德医药股票老虎国际,泰德医药行情,泰德医药股票行情,泰德医药股价,泰德医药股市,泰德医药股票价格,泰德医药股票交易,泰德医药股票购买,泰德医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰德医药(03880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}